TECX Valuation Metrics
FCF$-60.22M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
AvroBio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
Current Price
$28.53
-1.69%Profile
Valuation (TTM)
Market Cap$543.15M
P/E-7.32
EV—
P/B2.16
Shares Out19.04M
P/Sales—
Revenue$0.00
EV/EBITDA—
AvroBio Inc (TECX) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →TECX Valuation & Fair Value Analysis
AvroBio Inc (TECX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -7.32. Price-to-book ratio is 2.16. PEG ratio is 0.02.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of AvroBio Inc's intrinsic value.